Podcasts about Opioid use disorder

Season 5, episode 2 of the Just Us podcast places an emphasis on the treatment of substance use disorder in adolescents and young adults. Psychiatrist Leeallie Carter and family medicine physician Blake Fagan discuss the interactions between human biology, adverse childhood experiences, and substance use during this developmental period. The nuances of and barriers to adolescent SUD treatment are discussed in detail. Listen in to learn more!Resources: Substance Use Disorder Treatment Resources for Youth, Young Adults, and Families: https://opa.hhs.gov/adolescent-health/substance-use-adolescence Resources to Address the Opioid Epidemic: https://www.aap.org/en/patient-care/substance-use-and-prevention/resources-to-address-the-opioid-epidemic/ Substance Use Disorder Treatment Resources for Youth, Young Adults, and Families: https://www.samhsa.gov/substance-use/treatment/youth-and-families  We would love your feedback on our podcast!  Please take our listener survey to provide your comments.Music credit: "Carefree" Kevin MacLeod (incompetech.com)  Licensed under Creative Commons: By Attribution 4.0 Licensehttp://creativecommons.org/licenses/by/4.0/ Please provide feedback here:https://redcap.mahec.net/redcap/surveys/?s=XTM8T3RPNK 

In this Mental Health Moment, I am discussing - The 3 Main Medications used in treating Opioid Use Disorder: what they do and how they differ from one another. You can find information about this and other episodes on the website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lifelivedbetter.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Just a reminder - anything shared in this, and all other episodes is based on personal experiences and opinions. It is not to be viewed as professional counseling or advice and is solely the opinion of the individual and does not represent their employers or profession.  If you have a topic, you would like us to address in a future Mental Health Moment, let us know. Email us at ⁠⁠⁠Info@LifeLivedBetter.net⁠⁠⁠ We would love for you to rate our show and tell others about us. And remember, Knowledge leads to a Life Lived Better.

In this episode of Beyond The Abstract, Dr. Joao De Aquino joins the show to talk about his new article The Role of Childhood Trauma in Chronic Pain and Substance Use Among Individuals Receiving Methadone Treatment for Opioid Use Disorder featured in the May/June issue of the Journal of Addiction Medicine.   Article Link: The Role of Childhood Trauma in Chronic Pain and Substance Use Among Individuals Receiving Methadone Treatment for Opioid Use Disorder

On this podcast episode, I cover commonly used medications for opioid use disorder. Buprenorphine, methadone, and naltrexone are all potential options in OUD. I’ll discuss the pharmacology of each medication and the most common practice pearls that will show up in practice and on your board exams. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

In this episode of The Visible Voices Podcast, I sit down with Dr. Scott Weiner, emergency physician, associate professor at Harvard Medical School, and founder of system-wide substance use disorder programming.  Dr. Weiner shares the patient cases that set his life's work in motion, including a fatal overdose on Boston Common that changed how he understood both medicine and advocacy.  Scott addresses the troubling gap in opioid education in American schools, the promise of wearable technology for monitoring patients in recovery, and the real reasons overdose deaths are finally starting to decline. Opioid use disorder is not a moral failure — it is a public health crisis. ▶ Subscribe on YouTube @resaelewissmd — new Visible Voices episodes Wednesdays.

A retrospective comparison of two state-funded smartphone-based contingency management programs with different incentives  Drug and Alcohol Dependence This retrospective study compared outcomes for patients with stimulant use disorder enrolled in a smartphone-based contingency management program based on the amount of total incentives possible, either $75 (“low-value”) or $599 (“moderate-value”). The low-value program was based in New Jersey, funded through SAMHSA (which limited reimbursement to $75/patient at the time of implementation, which has since been increased), and rewarded completing drug testing, attending counseling visits, and completing CBT modules rather than abstinence over 16 weeks. The moderate-value program was funded by West Virginia's Medicaid managed care organizations, lasted up to 26 weeks, and largely rewarded negative drug screening results, with additional rewards for counseling and CBT modules. Patients in the moderate-value program submitted significantly higher rates of negative substance tests (36%, with an average of 3.2 negative tests) compared to those in the low-value group (24.7%, with an average of 24.8 negative tests).   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Best practices for hospital-based initiation of medications for opioid use disorder: A consensus statement JAMA Network Open This survey study used a 2-round Delphi process to develop expert consensus on best practices for hospital-based MOUD initiation for patients with OUD, with a goal to provide guidance on changing inpatient addiction treatment in response to increased synthetic opioids in the unregulated drug supply. A total of 42 expert clinicians participated; clinicians were considered a national expert if they had cared for at least 100 hospitalized patients with OUD in the last two years. There was consensus that buprenorphine and methadone initiation in the hospital setting were appropriate, with less support for hospital-based naltrexone initiation. Consensus was also reached to support rapid methadone initiation; high- and low-dose buprenorphine initiation; and provision of non-MOUD full agonist opioids for treatment of opioid withdrawal during methadone initiation, as a bridge to buprenorphine initiation, and for those declining MOUD.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM  

Access to Medications for Opioid Use Disorder Among Veterans With Homeless Experience in Permanent Supportive Housing JAMA Network Open This cohort study assessed 10,110 US veterans with homeless experience and opioid use disorder (OUD) residing in permanent supportive housing (PSH), in terms of what factors are associated with receipt of medications for opioid use disorder (MOUD).  Only 17% received MOUD within 12 months. Greater behavioral health engagement was associated with MOUD receipt, while older age, race minority status, and prior inpatient hospitalization were associated with lower odds. These results suggest that MOUD access in supportive housing should be expanding, which could require embedding addiction care into PSH teams, leveraging behavioral health touchpoints, and addressing persistent disparities.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Methadone Dose and Patient-Directed Discharge in Hospitalized Patients with Opioid Use Disorder JAMA Network This retrospective observational cohort study of 554 individuals examined rates of patient-directed discharge (PDD) among hospitalized patients with opioid use disorder who received methadone during the first 72 hours of hospitalization from July 2019 to June 2022. Higher doses of methadone were associated with a decreased rate of PDD. For each additional 10 mg of methadone received in the first 24 hours, there was a decrease in odds of PDD at 48 hours (adjusted OR 0.71). This study highlights the importance of adequate treatment of opioid withdrawal to reduce the risk of PDD.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Paige Soucie, Valley Leadership team lead for the Opioid Use Disorder Business, joined Arizona's Morning News to talk about Valley Leadership, stopping addiction, and the OUD Business Toolkit.

This is my annual poison prevention episode. The topic this year is The risks and benefits of using medications for opioid use disorder (MOUD) from a Poison Prevention Educator's Point of View. My guests are Angel Bivens, RPh and Dr. Wendy Stephan. This podcast is for educational purposes only and is not medical advice. Please consult a qualified healthcare professional for medical guidance specific to your situation.   Angel Bivens, RPh is the Managing Director at the Maryland Poison Center in Baltimore, Maryland.    Wendy Stephan, PhD is the Educator and Epidemiologist at the Poison Control Center in Miami, Florida. She is also on the Board of Directors of America's Poison Centers, which is the organization that supports all 53 Poison Centers in the United States.   To read the FULL show notes, visit https://www.thepharmacistsvoice.com.  Click the Podcast tab, and select episode 368.   Follow the podcast to get each new episode! Popular links are below.   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   Links and info from this episode Poison Help Line Number 1-800-222-1222 America's Poison Centers https://poisoncenters.org/  National Poison Prevention Week is March 15-21, 2026. Use the partner toolkit on https://piper.filecamp.com/s/i/OOt8k1JlBFCc08KH Florida Poison Control www.floridapoisoncontrol.org LinkedIn for Wendy: https://www.linkedin.com/in/wendy-s-315b70178/ Email Wendy wstephan@med.miami.edu X (Twitter): @floridapoison https://x.com/FloridaPoison  Instagram @floridapoisoncontrol https://www.instagram.com/floridapoisoncontrol/  Facebook: https://www.facebook.com/FloridasPCC/  Angel Bivens, RPh on LinkedIn https://www.linkedin.com/in/angelbivens/  Maryland Poison Center: https://www.mdpoison.com/  To find your local poison center: https://poisoncenters.org/  Poison Prevention Press: https://www.mdpoison.com/families/pppress.html (One-page, plain language e-newsletter published every other month on varying topics; all current and previous issues available Poison Prevention Press sign up: http://bit.ly/MPCSignUp) eAntidote Blog: blog.mdpoison.com  Facebook: MarylandPoisonCenter https://www.facebook.com/MarylandPoisonCenter  X (Twitter): @MDPoisonCtr https://x.com/MDPoisonCtr X (Twitter): @MPCToxtidbits https://x.com/MPCToxtidbits  Instagram: @MDPoisonCenter https://www.instagram.com/mdpoisoncenter/  YouTube: Maryland Poison Center https://www.youtube.com/@marylandpoisoncenter/videos  Resources with clinical information for pharmacists: ToxTidbits:  http://bit.ly/ToxTidbits (One-page clinical e-newsletter published monthly on various toxicologic topics; all current and previous issues available ToxTidbits sign up: http://bit.ly/TTBSignUp)   Other Poison Prevention Episodes The Pharmacist's Voice Podcast Episode 27 featuring Dr. Wendy Stephan (July 2020) The Pharmacist's Voice Podcast Episode 87 featuring Angel Bivens (March 2021) The Pharmacist's Voice Podcast Episode 141 featuring Angel Bivens (March 2022) The Pharmacist's Voice Podcast Episodes 203, 204, 205, 206, and 207 (March 2023) The Pharmacist's Voice Podcast Episode 268 featuring Wendy and Angel (March 2024) The Pharmacist's Voice Podcast Episode 321 featuring Wendy and Angel (March 2025)    Take-away messages from Episode 368 in March 2026: Overdose deaths declined between 2023 and 2024.  More than 23 million people are in recovery or have recovered from SUD.  Stigma associated with recovery needs to decline as the number of people in recovery increases. Recovery is possible, and it's probable. Poison Prevention Educators talk to students and communities about substance abuse prevention. Opioid use disorder has many possible entry points, including using pain killers from surgery or dental work, experimentation, and accidental use. Pharmacists have the opportunity to counsel on proper use and storage of MOUD. Counsel to take oral doses in private, so vulnerable individuals cannot see. Vulnerable individuals, like children or DD adults want to imitate the behavior of others. Avoid medication errors. Remove distractions while taking or giving medications, and read the label every time. Keep a personal MAR, if needed, to remember if a dose has been taken.  If a medication error happens, get help (Poison Help or 9-1-1), forgive yourself, and continue your road to recovery.  Narcan is import for anyone in recovery from opioid addiction to have. But, a person experiencing an OD will be unable to give themselves Narcan. Make sure your patients educate the people around them about what Narcan is, when to use it, and how to administer it.  As a general rule, counsel on calling 9-1-1 after giving a dose of Narcan. It can wear off.  Pharmacists should counsel on risks of keeping MOUD in the home: accidental use by a curious, opioid-naive child, confusion with other meds, accidental second dose, etc. Call Poison Help right away with exposure concerns, but skip right to 9-1-1 if the person is not breathing, unconscious, or having a seizure.  Poison Center Staff are experts in poison information. They help healthcare professionals and the general public with questions. If you call, you're in good hands. Adults of all ages may be in recovery. It's not just a health condition for young people.  Get Poison Help Line magnets for your pharmacy, and share them with your patients. If you need some magnets, call 1-800-222-1222.  March is Poison Prevention Month in the United States. National Poison Prevention Week in the US is March 15-21, 2026, and the theme is, "When the unexpected happens, Poison Help is here for you." There is a partner toolkit with images and talking points on https://piper.filecamp.com/s/i/OOt8k1JlBFCc08KH  A complete health history is important. Ask about recovery. Include "in recovery from opioid addiction" as a health condition at the pharmacy and with medical providers.  Advise patients to inscribe, "Do not give opioids" on medic alert jewelry. Similar advice, advise patient to include "do not give opioids" in the "health app" on their smartphone in case of emergency. Pharmacists (this is a tough one). If you see something, say something. Protect your patient's recovery. If something on your prescription monitoring program suggests that your patient is in recovery, but they are trying to fill prescriptions for opioids, protect their recovery. Maybe a well-meaning dentist, doctor, or surgeon wrote a prescription and didn't know the whole story. Or, maybe your patient wants to relapse. If you see something, say something, even if it feels awkward. Prevent relapses and maybe overdoses with patients who have a lower tolerance for opioids.  Be skeptical of natural products and supplements that have been promised to help with opioid withdrawal.  Terminology matters. Know your audience, and reflect their preferred language back to them. Avoid terms that are stigmatizing, like "junkie." When in doubt, ask the person you're speaking with how they prefer to call themselves.    Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX  ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Pronounce Drug Names Like a Pro © Online Course https://www.kimnewlove.com  ✅ Pharmacist Podcaster Book https://amzn.to/4iAKNBs  ✅ Podcasting Online Course https://www.kimnewlove.com/podcasting  ✅ Private Podcasting Coaching or Consulting https://www.kimnewlove.com/private-coaching  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with my coach, Dave Jackson from The School of Podcasting! Click my affiliate link: https://community.schoolofpodcasting.com/invitation?code=G43D3G  *New 12-4-25*

Emergency Department–Initiated Buprenorphine for Opioid Use Disorder JAMA Network This multicenter randomized study examined if 7-day extended-release injectable buprenorphine compared with sublingual buprenorphine to improve treatment engagement at 7 days.  It included 1,994 adult patients presenting to the emergency department with untreated opioid use disorder and a Clinical Opiate Withdrawal Scale (COWS) score of 4 or higher.  In treatment at 7 days, 40.5% were in the extended-release group and 38.5% were in the sublingual buprenorphine group, demonstrating no significant difference between groups. The study concluded that a 7-day extended-release injectable preparation of buprenorphine does not improve treatment engagement.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Opioid use disorder is the third most prevalent substance use disorder worldwide. Author Alexander Walley, MB, MSc, of Boston Medical Center and Boston University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the efficacy, safety, and practical considerations of treating patients with medications for opioid use disorder, opioid withdrawal, and opioid overdose. Related Content: Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose

Are you ready for NAEMSP?! In this special edition of the Prehospital Emergency Care podcast, host Greg Muller is joined by Guest Editor Remle Crowe to discuss the journal's latest special issue: "Enhancing Prehospital Care for Patients with Opioid Use Disorder". This episode goes beyond the statistics to explore the deeply human experiences behind the data. The episode features in-depth conversations with leading researchers on the front lines of the crisis: • Bringing Treatment to the Streets: Dr. Andrew Godfrey and Advanced Practice Paramedic Vicki Coles discuss the implementation of a prehospital buprenorphine program in Wake County, North Carolina, sharing lessons on clinician education and the vital role of "buprenorphine champions" in bridging the gap to long-term recovery. • The Pediatric Perspective: Drs. Stephen Sandelich and Garrett Cavaliere reveal surprising findings on how the opioid epidemic affects children and adolescents, discussing how the crisis transcends socioeconomic boundaries and why EMS must shift its approach to screening younger patients. • Innovative Strategies: A preview of the issue's 30 peer-reviewed articles, covering topics from drone-delivered naloxone and natural language processing to the qualitative lived experiences of clinicians facing burnout.   This episode serves as a vital primer for EMS professionals, policymakers, and researchers looking to move from traditional response models toward sustainable, patient-centered pathways for care.   Access the full special edition here: https://www.tandfonline.com/toc/ipec20/29/   As always THANK YOU for listening. Hawnwan Philip Moy MD (@pecpodcast) Scott Goldberg MD, MPH (@EMS_Boston) Jeremiah Escajeda MD, MPH (@jerescajeda) Joelle Donofrio-Odmann DO (@PEMems) Maia Dorsett MD PhD (@maiadorsett) Lekshmi Kumar MD, MPH(@Gradymed1) Greg Muller DO (@DrMuller_DO) Ariana Weber MD (@aweberMD4) Rebecca Cash PhD (@CashRebeccaE) Michael Kim MD (@michaeljukim) Rachel Stemerman PhD (@steminformatics) Nikolai Arendovich MD

Public Views About Opioid Overdose and People With Opioid Use Disorder JAMA Network Open This study completed a national web-based survey of 1552 adults in the United States in April 2025 to assess perceptions of opioid overdose deaths and opinions of people who use opioids. Those who responded to the survey primarily identified as female (60.5%) and aged 30-44 (33.7%). Political views varied, with 28.9% conservatives, 39.6% moderates, and 31.5% liberals. Most respondents viewed opioid overdose deaths as serious (88.2%). Respondents felt that people who use opioids (81%) and pharmaceutical companies (72.7%) were most responsible for reducing overdose deaths, with more liberals identifying pharmaceutical companies as responsible while moderates and conservatives more often identified individuals as responsible. 38.3% of respondents reported they were unwilling to have a person with OUD as a neighbor and 58.4% were unwilling to have a person with OUD marry into their family, with higher percentages of conservatives than liberals endorsing these beliefs.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

A highlight from exceptional sessions at the 2025 Midyear Clinical Meeting & Exhibition, this episode explores how pharmacists can bridge gaps in care for patients with opioid use disorder (OUD), highlighting strategies for prescribing and optimizing medications for OUD across primary, ambulatory, and acute care settings. We will discuss real-world examples, emerging practices like microdosing and direct-to-inject techniques, and ways pharmacists can make a tangible difference in improving patient outcomes. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, Dr. Blythe Bynum joins the show to discuss her new article titled Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder, featured in the November/December issue of the Journal of Addiction Medicine. Dr. Blythe Bynum is an assistant professor in the Department of Obstetrics and Gynecology at Thomas Jefferson University in Philadelphia, Pennsylvania. She is a board certified OBGYN with fellowship training in Complex Family Planning.    Article Link: Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder

Moderator: James P. Rathmell, M.D. Participants: Mark Bicket, M.D., Ph.D. and Lynn Kohan, M.D. Articles Discussed: Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016-2022 Rising Treatment for Substance Use Disorder Presents New Challenges for Anesthesiologists as Perioperative Medicine Specialists Transcript

In this episode, James Campbell, MD, MS, FAAP, discusses the AAP's updated recommendations for COVID-19 vaccines in infants, children and adolescents. David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Scott Hadland, MD, MPH, MS, FAAP, about the use of buprenorphine for the treatment of opioid use disorder in young people. For resources go to aap.org/podcast.

State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015–23 Health Affairs While medications for opioid use disorder (MOUD) is effective treatment, most patients with OUD don't receive it and prior authorization (PA) has been a barrier to access. Researchers looked at state policies trying to address this barrier, specifically for private health insurance, between 2015 and 2022. Some states adopted “full prohibitions” against PAs while others adopted “partial prohibitions” that allowed PA under some circumstances. Overall, the number of states with at least some prohibition increased from 2 in 2015 to 22 in 2023. In addition, 7 states adopted “full prohibitions” initially, while 15 adopted “partial prohibitions”, with 4 of those 15 transitioning to “full prohibitions” later. Additional research will be needed to assess the impact of these prohibitions, but this study elucidates the current landscape of policy.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Dr. Jennifer McNeely stops by the show to discuss her new article Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service.   Article Link: Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service

Medications for Opioid Use Disorder Playbook Agency for Healthcare Research and Quality (AHRQ)  The AHRQ Integration Academy developed the Medications for Opioid Use Disorder Playbook as a practical guide for providing medications for opioid use disorder (MOUD) and immediate care for patients with OUD in primary care and other ambulatory care settings. It is interactive, web-based, and has the latest guidance, tools, resources, and examples that address key aspects of MOUD implementation. The MOUD Quick Start Guide covers the essentials of low-threshold care, while the balance of the Playbook offers more in-depth resources and guidance for those practices interested in working toward more comprehensive, whole-person care. The low-threshold approach ensures immediate access to MOUD, eliminating barriers for both patients and providers.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Dr. Pouya Azar stops by the show to talk about his recent article Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. He discusses the potential benefits of transitioning patients with opioid use disorder from traditional to extended-release or long-acting buprenorphine within 7 days or 24 hours, respectively, of treatment, as well as challenges and future questions that arose from his narrative review. Pouya Azar, MD, FRCPC, DABAM, is a clinician-scientist in addiction psychiatry and pain medicine based in Vancouver, British Columbia, Canada. He serves as co-medical manager of the Complex Pain and Addiction Service (CPAS) at Vancouver Coastal Health, a consult service providing management of pain, mental health disorders, and substance use disorders across Vancouver General Hospital, the University of British Columbia (UBC) Hospital, and GF Strong Rehabilitation Centre. He is also an assistant professor (tenure-track) in the UBC Department of Psychiatry, research scientist co-lead of the Substance Use Disorder Clinical Research Unit at the BC Centre for Excellence in HIV/AIDS, and a physician at the Vancouver General Hospital Transitional Pain Clinic. Dr. Azar's clinical and translational research focuses on developing novel opioid agonist treatment initiation and withdrawal management protocols, medical devices, digital health apps, and prevention programs to improve patient outcomes. - Article Link: Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative

Patients with opioid use disorder (OUD) present to the hospital setting for a variety of reasons, so emergency and inpatient pharmacists increasingly need to have a working knowledge of OUD, its treatment modalities, and other factors that affect the management of these patients. This podcast will discuss aspects of care from presentation to discharge, dispel common misconceptions about the management of OUD and acute pain, and promote a standardized approach to care of an often-marginalized population of patients. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Opioids are powerful drugs that can help people who are struggling with pain from severe injuries or illness, but the compounds are also highly addictive and the CDC says overdose is one of the leading causes of injury death for adults in the U.S. with rates quickly climbing from the early 2000s. In recent years, overdose deaths have declined in most of the country but remain high in Alaska. Why are rates still elevated here and what is being done to help people stay safe from illicit drugs? We discuss it on this Talk of Alaska.

Interview with Anna D. Ratzliff, MD, PhD and Andrew J. Saxon, MD authors of Collaborative Care for Opioid Use Disorder in Primary Care: A Hybrid Type 2 Cluster Randomized Trial. Hosted by John Torous, MD. Related Content: Collaborative Care for Opioid Use Disorder in Primary Care

Interview with Anna D. Ratzliff, MD, PhD and Andrew J. Saxon, MD authors of Collaborative Care for Opioid Use Disorder in Primary Care: A Hybrid Type 2 Cluster Randomized Trial. Hosted by John Torous, MD. Related Content: Collaborative Care for Opioid Use Disorder in Primary Care

Association between housing status and mental health and substance use severity among individuals with opioid use disorder and co-occurring depression and/or PTSD  BMC Primary Care  This is a cross-sectional analysis of associations between housing status and mental health and substance use severity among primary care patients with co-occurring disorders. The study is a sub-analysis using data from the Collaboration Leading to Addiction Treatment and Recovery from other Stresses randomized controlled trial, which tested the Collaborative Care Model for primary care patients with OUD and co-occurring depression and/or PTSD. Of 797 patients in the study, 13% were currently unhoused, 24% were unstably housed, and 63% were stably housed. Those who were unhoused were on average younger and had not used prescribed MOUD in the past 30 days. The analysis found that being unhoused or unstably housed was significantly associated with higher PTSD symptom severity, depression symptom severity, opioid use severity, and opioid overdose risk behaviors compared to those who were stably housed.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Justin Coleman speaks with Hester Wilson, Chief Addiction Medicine Specialist for NSW, and pharmacist Jillian Kanck about the medicines used in the treatment of opioid dependence. They explain how opioid dependence is diagnosed and discuss the advantages of long-acting buprenorphine, as well as the place of sublingual buprenorphine and methadone in treatment. Read the full article by Hester and Jillian in Australian Prescriber.

In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness, and how can proper dosing make the difference between recovery and relapse? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Methadone for Managing OUD

Medications like buprenorphine are important tools in the spectrum of care for opioid use disorder, so why is there so much stigma around their use?

Dr. Jarratt Pytell stops by the show to discuss his recent article featured in the Journal of Addiction Medicine titled Post Void Residuals: Medications for Opioid Use Disorder, Patient Outcomes, and How Not to Get Fooled by Urine Toxicology Results - Article Link: Void Residuals: Medications for Opioid Use Disorder, Patient Outcomes, and How Not to Get Fooled by Urine Toxicology Results

Dive into practical, evidence-based approaches to managing pain in patients with opioid use disorder, bust common myths, and explore strategies to support patients. This episode will enhance your skills in providing holistic, patient-centered care. We're joined by Dr. Jessica Merlin, @JessicaMerlinMD (University of Pittsburgh).  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Credits Producer, Show Notes, Infographics: Carolyn Chan MD, MHS Hosts: Carolyn Chan, MD, MHS and Shawn Cohen MD Reviewer: Payel Jhoom Roy MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Jessica Merlin MD, PhD, MBA Sponsor: JournalFeed Try JournalFeed free for 7 days — and get 20% off your first year with code CURB25 at journalfeed.org/curb. Sponsor: Freed Usecode: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor: Mint Mobile Get your summer savings and shop premium wireless plans at MINTMOBILE.com/CURB

Dive into practical, evidence-based approaches to managing pain in patients with opioid use disorder, bust common myths, and explore strategies to support patients. This episode will enhance your skills in providing holistic, patient-centered care. We're joined by Dr. Jessica Merlin, @JessicaMerlinMD (University of Pittsburgh).  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Credits Producer, Show Notes, Infographics: Carolyn Chan MD, MHS Hosts: Carolyn Chan, MD, MHS and Shawn Cohen MD Reviewer: Payel Jhoom Roy MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Jessica Merlin MD, PhD, MBA Sponsor: JournalFeed Try JournalFeed free for 7 days — and get 20% off your first year with code CURB25 at journalfeed.org/curb. Sponsor: Freed Usecode: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor: Mint Mobile Get your summer savings and shop premium wireless plans at MINTMOBILE.com/CURB.

In this episode of Health Talks, we sat down with Dr. Ruchi Fitzgerald from PCC Wellness Health Center to explore the topic of treatments for substance use disorder. Specically, long-acting injectables (LAIs) and other treatments for opioid use disorder (OUD). Dr. Fitzgerald shares her clinical journey into this field, the barriers patients face in staying on treatment, and how new treatments may offer a solution by providing stability and continuity of care. We dive into how treatments work, the growing eligibility among patients, and strategies for discussing these options with those considering treatment. Dr. Fitzgerald also highlights the value of listening to individuals with lived experience and how integrating harm reduction, behavioral health, and primary care can lead to more compassionate, effective care models.

Listen in as our expert panel discusses medications for management of opioid use disorder. They'll review strategies to optimize buprenorphine use and clarify the role of methadone and naltrexone.Special guest:Tyler J. Varisco, PharmD, PhDUniversity of Houston College of Pharmacy Assistant Professor, Department of Pharmaceutical Health Outcomes and PolicyAssistant Director, The PREMIER CenterYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLM, Clinical Associate Professor of Family Medicine for the Prisma Health/USC School of Medicine Greenville Family Medicine Residency Program at the University of South Carolina School of Medicine, GreenvilleCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Varisco reports a financial relationship [cardiology, inflammatory bowel disease] with HEALIX Infusion Therapy (research consultant).The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ: Management of Opioid Use DisorderChart: Treatment of Opioid WithdrawalFAQ: Treatment of Acute Pain in Opioid Use DisorderFAQ: Meds for Opioid OverdoseSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

INterview with nurse practitioner Theresa Baxter

Hospital Addiction Consultation Service and Opioid Use Disorder Treatment JAMA Internal Medicine While medication for opioid use disorder (MOUD) is effective, many patients with OUD do not receive it, particularly in hospitalized settings. In this randomized trial they evaluated the Substance Use Treatment and Recovery Team (START) model, a team of an addiction medicine provider and a care manager, and provided motivational interviewing, discharge planning and telephone follow-up for one month. Patients who received the START intervention were more likely to receive MOUD (aRR=2.10) and connect to OUD care after discharge (aRR=1.49). In addition, these patients were more likely to have an OUD-focused discharge plan (aRR=1.8), initiate or continue MOUD post discharge (aRR=1.71), and see a clinician for OUD post discharge (aRR=1.89). These findings support use of hospital-based addiction consult services to address this healthcare gap.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Interview with Itai Danovitch, MD, author of Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial, and Michael A. Incze, MD, MSEd, author of Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization. Hosted by Eve Rittenberg, MD. Related Content: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization When Usual Care Is Subpar Care for Hospitalized Patients With Opioid Use Disorder

Interview with Itai Danovitch, MD, author of Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial, and Michael A. Incze, MD, MSEd, author of Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization. Hosted by Eve Rittenberg, MD. Related Content: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization When Usual Care Is Subpar Care for Hospitalized Patients With Opioid Use Disorder

About this episode: People come to the emergency department seeking all kinds of urgent care. What if they could also get treatment for opioid addiction? In this episode: a look at how one rural hospital started prescribing buprenorphine to ER patients, and how scaling up treatment while reducing stigma at hospitals across the US is now helping thousands of patients every year. Guest: Arianna Campbell is an emergency department and addiction medicine PA at Marshall Medical Center in Placerville, California. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: USACS Physician Assistant, Ariana Campbell, PA-C, Aims to Eliminate the Stigma of Substance Use Through Education and Intervention—The Shift Blog The New Federal Regulations Aimed At Making Methadone More Accessible—And Less Stigmatizingcvb x—Public Health On Call (April 2024) A New Type of Overdose Response—Public Health On Call (March 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

In this episode, Dr. Ekaterina Pivovarova joins host Shawn McNeil to discuss the findings from her new article Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. Dr. Pivovarova is a licensed clinical psychologist and an associate professor in the Department of Family Medicine and Community Health at the University of Massachusetts Chan Medical School. - Article link: Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers

Dr. David Krag and his team are sifting through around 43,000 studies about opioids and addiction to create an easy-to-access research database.

About this episode: A new report from the Bloomberg American Health Initiative finds that the U.S. lags behind many other high-income countries in life expectancy. In this report, researchers found that babies born 40 years ago in the U.S. and U.K could expect to live to the same age. Today, however, life expectancy is nearly three years shorter for those on our side of the Atlantic Ocean. In this episode: a look at the four main causes of death driving this gap—all of which are preventable—and how one of the world's richest countries that spends the most on healthcare is continually failing to improve the health of its people. Guest: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs, the largest center at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: A Tale of Two Countries: The Life Expectancy Gap Between the United States and the United Kingdom—The Bloomberg American Health Initiative Americans Die Younger Than U.K. Counterparts Due to Four Preventable Causes—Johns Hopkins Bloomberg School of Public Health Expanding Access to Methadone Treatment for Opioid Use Disorder in Carceral Settings—Johns Hopkins Bloomberg School of Public Health Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on X @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

Every week, the equivalent of a high-school classroom's worth of students (an average of 22 adolescents) dies of drug overdoses in the United States. Join us and expert guest Dr. Scott Hadland (Mass General for Children, Harvard Medical School) as we explore Opioid Use Disorder, a rapidly evolving disease affecting our youth. Dr. Hadland provides a big picture understanding of this complex problem but also gives practical day to day tools for tackling OUD in teens. Come and be surprised by how much better you can navigate opioid use among teens. 

ABOUT THE EPISODE:In 2020, a documentary film titled "The Final Fix" introduced the public to a new treatment for opioid use disorder.  The claims of the neuroelectric therapy (NET) device are bold: opiate detox in 3-5 days with little or no withdrawal symptoms, discomfort, or cravings. Since the film's release, I have personally known three people who acquired NET treatment for their kids, including two from the Hopestream community. All have had great experiences.In 2021, double-blind trials of more than 100 people experiencing opioid use disorder began and the NET Device for OUD treatment was approved by the FDA in May of this year.In this episode, I spoke with Jeff Lott, director of communications at NET Recovery. We discussed the surprising origins of this medical technology, how NET was accidentally discovered by a Scottish surgeon working in Hong Kong, the fact that its groundbreaking results are not a panacea for recovery, and plans for the future of the NET Device for widespread adoption and use in the treatment industry.EPISODE RESOURCES:A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinenceRevolutionary Kentucky-based opioid use disorder treatment device receives FDA approvalNET Recovery websiteIsiah House NET Recovery InformationThis podcast is part of a nonprofit called Hopestream CommunityLearn about The Stream, our private online community for momsLearn about The Woods, our private online community for dadsFind us on Instagram: @hopestreamcommunityDownload a free e-book, Worried Sick: A Compassionate Guide For Parents When Your Teen or Young Adult Child Misuses Drugs and AlcoholHopestream Community is a registered 501(c)3 nonprofit organization and an Amazon Associate. We may make a small commission if you purchase from our links.

Two-time Emmy and three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald, interviewed Dr. Michael Giles. Our Virtual Dosing Window™ allows patients to record their take-homes by using a phone or computer to scan the QR code on their methadone bottles and then recording a video of themselves dosing for their care team to review. This patented solution helps build trust between OTP patients and their care teams, empowering clinics with real-time insights to make informed treatment decisions. Sonara also increases patients' likelihood of earning more take homes, which in turn improves program retention rates. Since starting Sonara in 2020, Dr. Giles has expanded the solution to a network of modernized, tech-enabled clinics in 11 states that provide accessible, patient-centered care for individuals struggling with OUD. Sonara® is on a mission to support OTP patients, with a remote dosing solution that makes it easier for people with opioid use disorder to commit to their methadone treatment programs, so they can get their lives back. Sonara provides OTPs with the confidence they need to approve more take-home doses responsibly, to improve the quality of life for patients and expand treatment accessibility for those who live farther away from clinics. Notable investors in Sonara include Mark Cuban and First Trust Capital. With Sonara, OTP patients can achieve their treatment goals without putting their lives on hold. To learn more about partnering with Sonara or bringing the Virtual Dosing Window to your OTP, visit sonarahealth.com/contact-us to get in touch. #STRAW #SHMS  Support the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Two-time Emmy and three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald, interviewed Dr. Michael Giles. Our Virtual Dosing Window™ allows patients to record their take-homes by using a phone or computer to scan the QR code on their methadone bottles and then recording a video of themselves dosing for their care team to review. This patented solution helps build trust between OTP patients and their care teams, empowering clinics with real-time insights to make informed treatment decisions. Sonara also increases patients' likelihood of earning more take homes, which in turn improves program retention rates. Since starting Sonara in 2020, Dr. Giles has expanded the solution to a network of modernized, tech-enabled clinics in 11 states that provide accessible, patient-centered care for individuals struggling with OUD. Sonara® is on a mission to support OTP patients, with a remote dosing solution that makes it easier for people with opioid use disorder to commit to their methadone treatment programs, so they can get their lives back. Sonara provides OTPs with the confidence they need to approve more take-home doses responsibly, to improve the quality of life for patients and expand treatment accessibility for those who live farther away from clinics. Notable investors in Sonara include Mark Cuban and First Trust Capital. With Sonara, OTP patients can achieve their treatment goals without putting their lives on hold. To learn more about partnering with Sonara or bringing the Virtual Dosing Window to your OTP, visit sonarahealth.com/contact-us to get in touch. #STRAW #SHMS  See omnystudio.com/listener for privacy information.

On this episode we discuss the management of opioid use disorder. We begin by describing its clinical presentations, etiologies, and pathophysiology. We then compare and contrast the efficacy, safety profiles, and appropriate use of medications for opioid use disorder, behavioral therapies, and patient monitoring in treating opioid use disorder.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! We want to give a big thanks to our sponsor, High-Powered Medicine. HPM is a book/website database of summaries for over 150 landmark clinical trials. You can get a copy of HPM, written by Dr. Alex Poppen, PharmD, at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

An update of our 2020 series, in which we spoke with physicians, researchers, and addicts about the root causes of the crisis — and the tension between abstinence and harm reduction. SOURCES:Gail D'Onofrio, professor and chair of emergency medicine at the Yale School of Medicine and chief of emergency services at Yale-New Haven Health.Keith Humphreys, professor of psychiatry and behavioral sciences at Stanford University.Stephen Loyd, chief medical officer of Cedar Recovery and chair of the Tennessee Opioid Abatement Council.Nicole O'Donnell, certified recovery specialist at the University of Pennsylvania's Center for Addiction Medicine and Policy.Jeanmarie Perrone, professor of emergency medicine at the University of Pennsylvania.Eileen Richardson, restaurant manager. RESOURCES:“Toward Healthy Drug Policy in the United States — The Case of Safehouse,” by Evan D. Anderson, Leo Beletsky, Scott Burris, and Corey S. Davis (The New England Journal of Medicine, 2020).“Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder,” by Leo Beletsky, Kevin Fiscella, and Sarah E. Wakeman (JAMA Psychiatry, 2018).“Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence,” by Gail D'Onofrio, Patrick G. O'Connor, Michael V. Pantalon, Marek C. Chawarski, Susan H. Busch, Patricia H. Owens, Steven L. Bernstein, and David A. Fiellin (JAMA, 2015).“Buprenorphine-Naloxone Therapy In Pain Management,” by Lucy Chen, Kelly Yan Chen, and Jianren Mao (National Institutes of Health, 2014).“Prevalence and Correlates of Street-Obtained Buprenorphine Use Among Current and Former Injectors In Baltimore, Maryland,” by Jacquie Astemborski, Becky L. Genberg, Mirinda Gillespie, Chris-Ellyn Johanson, Gregory D. Kirk, Shruti H. Mehta, Charles R. Schuster, and David Vlahov (U.S. National Library of Medicine National Institutes of Health, 2014).“The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy,” by Art Van Zee (U.S. National Library of Medicine National Institutes of Health, 2009). EXTRAS:"Why Is the Opioid Epidemic Still Raging?" series by Freakonomics Radio (2024)."The Opioid Tragedy, Part 1: 'We've Addicted an Entire Generation,'" by Freakonomics Radio (2020).“The Truth About the Vaping Crisis,” by Freakonomics Radio (2019).